الفهرس 
Myocardial infarctionOnly 14 pages are availabe for public view
 |  | from | 220 |  |  |
| | | from | 220 | | |
Abstract
The aim of the present study to elucidate the potential pharmacological outcomes of carvedilol combination with co enzyme Q10 in isoprenaline-induced myocardial infarction in rats.
Study Design: Carvedilol and/or co enzyme Q10 was given once daily for 14 consecutive days at doses of 10 mg/kg orally after administration of two doses of ISP (85 mg/kg; s.c. at 24h interval). Results: In the present work, evidence of cardiac damage was based on three main measures; ECG criteria, histopathological findings, electron microscopy and in addition to CK-MB. Isoprenaline induced myocardial infarction in rats showed increase in serum CK-MB, significant tachycardia, and ST segment elevation coupled with prolonged QTC interval., increased absolute and relative heart weight, increased serum CK-MB, myofibrillar disarrangement and several histological changes. ISP induced lipid profile alteration expressed as elevation in triglyceride, cholesterol and LDL with reduction in HDL.
These lipid alterations were modified by treatment with Carvedilol and/or co enzyme Q10. As indicators of oxidative stress, ISP increased cardiac lipid peroxide levels and decreased the levels of cardiac GSH and serum total antioxidant capacity. Moreover, ISP increased the expression of TNF-α and NF-κB which further promote apoptotic cell death and increases caspases 3 and 9 activities.
Conclusion: The present study provides the evidence that carvedilol and co enzyme Q10 treatment could reduce the myocardial injury and improves cardiac function in ISP-induced MI. These effects are mostly via its hypolipidemic, antioxidant, and anti-inflammatory effects that suppress caspase mediated apoptotic pathway. Co enzyme Q10 has additional effects if combined with carvedilol.